targeted cancer therapy Archives

Oncotarget News

FDA-Approved MI Cancer Seek Test Enhances Tumor Profiling for Precision Oncology

August 15, 2025

Accordingly, MI Cancer Seek represents a safe and effective comprehensive molecular test option supporting biomarker-directed care for oncology patients.”BUFFALO, NY - August 15, 2025 – A new research paper was published... read more

Oncotarget

HER2-Mutated NSCLC in Brazil Shows Diverse Genetic Patterns and Treatment Gaps

June 27, 2025

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented populations, emphasizing the need for comprehensive molecular profiling and expanded access to targeted therapies.”BUFFALO, NY -... read more

Oncotarget

New Genetic Mutation Linked to Drug Resistance in Non-Small Cell Lung Cancer Patient

February 6, 2025

Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired resistance to lorlatinib after 6 months... read more

Oncotarget

Complete Response to Encorafenib + Binimetinib in BRAF V600E-Mutant Tumor

October 29, 2024

This case report highlights the importance of full tumor genotyping to identify potentially actionable targets in rare tumors such as malignant glomus tumors.”BUFFALO, NY- October 29, 2024 – A new... read more

Oncotarget

Targeting CD47/SIRPα “Do Not Eat Me” Axis: Advances and Challenges in Cancer Therapy

September 11, 2024

Numerous phagocytosis checkpoints and ‘do not eat me’ signals (i.e., CD47, CD24, MHC-I, PD-L1, STC1, and GD2) have recently been recognized as potential therapeutic targets.”BUFFALO, NY- September 11,... read more

Figure 1: Tumor intrinsic and extrinsic factors in the periphery that can serve as proxies of tumor burden. Peripheral surrogates

Oncotarget

Peripheral Surrogates of Tumor Burden to Guide Therapeutic Strategies for HPV-Associated Malignancies

August 14, 2023

We discuss existing clinical data on these surrogates of tumor burden and their potential in evaluating efficacy of immunotherapy in HPV-associated malignancies.” BUFFALO, NY- August 14, 2023 – A new... read more

Figure 1: Combined targeting of SMO and BRD4 as a potential therapeutic strategy against melanoma.

Oncotarget

Novel Therapeutic Strategy Against Melanoma: Combined Targeting of Hedgehog Signaling and BRD4

July 19, 2023

This evidence strengthens the relevance of the findings by Pietrobono et al., shedding light on the potential application of SMO inhibitors in concert with BRD4 inhibitors.”BUFFALO, NY- July 19,... read more

Oncotarget

DPDT Anticancer Activity in Human Colon Cancer HCT116 Cells

June 26, 2023

Altogether, our results show that DPDT preferentially targets HCT116 colon cancer cells likely through DNA topoisomerase I poisoning.”BUFFALO, NY- June 26, 2023 – A new research paper was published in... read more

Figure 1: Proposed pathway of ACSL4-mediated stimulation of quadruple negative breast cancer cells

Oncotarget

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer

June 14, 2023

ACSL4 has been demonstrated to play a pivotal role in both normal physiology as well as in a variety of disease states, including breast and other cancers.”BUFFALO, NY- June... read more

Figure 1: Canonical Src regulation involves the transition from an inactive closed state to an active open form.

Oncotarget

Targeting the Src N-Terminal Regulatory Element in Cancer

June 9, 2023

Src is a recognized oncotarget.”BUFFALO, NY- June 9, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “Targeting the Src N-terminal regulatory... read more